The present invention relates to novel Lactic Acid Bacteria strains Lactobacillus reuteri selected from the group comprising Lactobacillus reuteri DSM 32229, Lactobacillus reuteri DSM 32230, Lactobacillus reuteri DSM 32231 and Lactobacillus reuteri DSM 32232 and products comprising these strains. The present invention also relates to a use of one or more Lactic Acid Bacteria strains as a probiotic for the treatment of an inflammation and infection, such as mastitis and/or thrush, especially after topical administration of said strains.